PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Am J Addict. Author manuscript; available in PMC Nov 1, 2009.
Published in final edited form as:
Am J Addict. 2008; 17(6): 463–468.
doi:  10.1080/10550490802409074
PMCID: PMC2657877
NIHMSID: NIHMS82901
Gender Differences in Predictors of Treatment Attrition with High Dose Naltrexone in Cocaine and Alcohol Dependence
Jesse J. Suh, Psy.D.,1,2 Helen M. Pettinati, Ph.D.,1 Kyle M. Kampman, M.D.,1,2 and Charles P. O’Brien, Ph.D., M.D.1,2
1Center for Studies of Addiction, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA
2Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
Corresponding Author: Dr. Jesse J. Suh, Center for Studies of Addiction, Department of Psychiatry, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, Pennsylvania 19104, (215) 222-3200 (ext. 130), Fax: (215) 386-6770, E-Mail: Suh_J/at/mail.TRC.Upenn.edu
Recently, we reported that naltrexone at 150mg/day significantly decreased cocaine and alcohol use for men, but not women with co-occurring cocaine and alcohol dependence. The present study is an exploratory investigation of predictors that explain the different gender response to naltrexone, with a particular focus on differential predictors of treatment attrition. No significant predictors were associated with treatment discontinuation in men. Women, however, were more likely to discontinue treatment when reporting severe pre-treatment psychiatric problems, or nausea while in treatment. Further research on the impact of pre-treatment and in-treatment gender differences with naltrexone is warranted.
Keywords: Naltrexone, cocaine dependence, alcohol dependence, adverse events, nausea, treatment attrition
Naltrexone, an opioid antagonist, is a FDA-approved medication for alcohol dependence.1, 2 It has been shown to be efficacious, but good adherence is necessary for successful outcomes.35 For example, naltrexone treatment is significantly advantageous over placebo, only when alcohol dependent patients maintain high medication adherence.6, 7 In recent investigations, patients’ reports of nausea during naltrexone treatment predicted poor medication adherence810 and treatment discontinuation.11 Nausea is one of the most common adverse events reported in naltrexone treatment,11, 12 and O’Malley et al8 previously reported there may be gender differences in the experience of this side effect, possibly due to increased sensitivity of the opioid pathways in women compared to men.8 Thus, patients’ experience of naltrexone-associated nausea may limit its effectiveness, via poor medication adherence, and this finding may be seen more frequently in women than in men.
In a large randomized, double-blind, placebo-controlled investigation of high-dose naltrexone (150mg) in cocaine and alcohol dependent (CAD) patients, Pettinati et al.13 reported that men in naltrexone treatment (vs., placebo) reduced their cocaine and alcohol use, whereas women taking naltrexone had poorer outcomes than the women taking placebo. In addition, there appeared to be an intriguing but non-significant difference in treatment attrition rates between the two subgroups of naltrexone-treated men and women (27.6% vs. 45.8%, respectively), but not in placebo subgroups. Given the trends of women discontinuing treatment at a higher rate than men in naltrexone condition and more frequent reports of nausea in female (vs. male) patients, Pettinati et al.13 suggested that a high daily dose of naltrexone (150 mg/day) might be problematic for women. In contrast, one preclinical study reported that a 100 mg/day dosage of naltrexone was safe and well-tolerated in both men and women.14 Two previous studies reported gender differences in outcome among alcohol dependent samples,11, 15 but did not explore whether the outcome differences between men and women were medication-related.
Despite the promising results of the large clinical trial of high-dose naltrexone treatment for CAD men, the gender disparity in response to high-dose naltrexone raises important clinical issues, such as potential gender differences in naltrexone-associated adverse events and treatment non-adherence. The present exploratory study is a secondary analysis evaluating whether there are gender-specific differences in predictors of treatment attrition between CAD men and women who received a high-dose of naltrexone versus placebo, with one of two types of psychosocial therapies. Variables affecting differential outcome or attrition for men and women, including experience of nausea,8, 13 substance use,16 and severity of psychiatric problems1720 were considered. We chose six variables to predict treatment attrition for men and women. They included: 1) randomized medication treatment condition (high-dose naltrexone or placebo); 2) randomized psychosocial treatment condition [cognitive behavioral therapy (CBT) or a medical management treatment model (BRENDA)21]; 3) psychiatric severity prior to treatment, as women present with more severe psychiatric problems than men prior to substance use treatment, leading to treatment attrition1720; 4) experience of nausea, which is the most common adverse effect associated with the standard dose and high-dosage naltrexone, and a more frequently reported adverse event in women than men in naltrexone treatment8, 13; 5) alcohol use during treatment; and 6) cocaine use during treatment.
Participants
Participants were cocaine dependent and alcohol dependent (DSM-IV) patients between the ages of 18 and 65 who were seeking treatment at a university-affiliated outpatient, substance addiction treatment research facility in Philadelphia, PA. Detailed descriptions of the participants have been reported elsewhere.13
Of the 229 patients who were administered medical and psychosocial evaluations, laboratory tests, and Structured Clinical Interview for DSM-IV,22 164 patients (116 men and 48 women) were eligible for the study (i.e., met all of the inclusion criteria and did not meet any exclusion criteria), provided written consent, and were randomized. This study was approved by the University of Pennsylvania Institutional Review Board.
Measures
Self-reported Substance Use
Time-line Follow-Back (TLFB)23 techniques were used to gather self-reports of detailed daily alcohol and cocaine use at the weekly treatment visits. In studies with alcohol and drug dependent populations, there has been good agreement between TLFB data and collateral and biological data.2426 The primary outcome TLFB measures were the frequencies of alcohol and cocaine use. TLFB was administered by a trained research technician at baseline assessment and at each weekly visit throughout the trial.
Psychiatric Severity
The psychiatric severity composite score of the Addiction Severity Index 5 (ASI-5)27 was used to obtain the severity of psychiatric problems. ASI-5 has demonstrated moderate to excellent internal consistency, test, retest, and inter-rater reliabilities in different groups of substance abusers.28, 29 A trained research technician at the baseline assessment administered the ASI-5.
Report of Nausea
A research physician met with patients weekly and gathered information about adverse events. Subjects were asked to report any new symptoms, the number of days experiencing the symptoms, and the severity of symptoms ranging from “very mild” to “very severe.” The research physician also recorded any medical decisions or resolutions taken by the physician.
Treatment Attrition
Treatment attrition was defined as discontinuing medication treatment, either high-dose naltrexone or placebo, for three or more consecutive weeks over the planned treatment course. Medication discontinuation was monitored by weekly pill counts (i.e., blister packs).
Procedures
This was a randomized, placebo-controlled, double-blind factorial (2×2) 12-week trial of naltrexone/placebo and psychosocial treatments for CAD. Participants were randomly assigned to one of the following four treatment conditions: naltrexone-CBT (33 males, 11 females); naltrexone-BRENDA (25 males, 13 females); placebo-CBT (26 males, 11 females); or placebo-BRENDA (32 males, 13 females). Participants assigned to the placebo condition were prescribed placebo pill(s) of identical appearance in identical packaging. During the trial, participants were scheduled to meet weekly with a research physician for medications, and either a BRENDA or CBT clinician for the psychosocial intervention. Research Technicians met with the participants weekly to obtain various study-related measures. Detailed descriptions of the procedures have been reported elsewhere.13
Manually-guided CBT, an individual psychotherapy treatment based on the relapse prevention model of Marlatt and Gordon30 and adapted by Carroll31 for treatment of CAD, was conducted by CBT-trained, experienced, masters- or doctorallevel therapists in 45-minute weekly sessions for the duration of the 12-week treatment trial. BRENDA is a primary care based, manualized psychosocial intervention to enhance treatment adherence and motivation to achieve health.21, 32 Participants assigned to the BRENDA condition attended weekly 30-minute individual meetings with a BRENDA-trained and experienced nurse practitioner during the 12-week treatment period.
Data Analyses
All randomized participants were included in the data analysis, regardless of whether the subject discontinued treatment. Subjects were not dropped from any study activity, unless they specifically requested that they not be contacted. The frequency of nausea was obtained by dividing the number of reports of nausea (i.e., severity ranging from mild to very severe) by the number of meetings held between the subject and the research physician. Students’ t-tests and chi-square analyses were conducted to examine the gender differences within the continuous variables (e.g., psychiatric severity, frequency of nausea reporting, alcohol and cocaine use) and categorical variables (e.g., type of randomized treatments and treatment attrition), respectively.
We performed two separate logistic regression analyses, for men and women, to predict treatment attrition, using six predictor variables: 1) medication treatment (highdose naltrexone or placebo); 2) psychosocial treatment (CBT or BRENDA); 3) psychiatric severity at baseline; 4) frequency of nausea reporting during the treatment; 5) frequency of cocaine use during the treatment; and 6) frequency of alcohol use during the treatment. Missing data for alcohol and cocaine use were imputed as drug use (“positive”); that is a standard practice in clinical trials.33 Although the purpose of the current study is to examine the interaction between gender and covariate variables in a model predicting the treatment attrition, our analyses will be limited to two separate gender analyses due to an unbalanced and small sample. Because the current study is exploratory, a backward stepwise selection based on likelihood ratio (LR) statistics were used to fit the model, using an alpha entry criterion of .05 and an alpha deletion criterion of .10. All analyses were conducted using the SPSS 12.0 software package.
Gender differences on selected pre-treatment and in-treatment variables
Demographic pre-treatment and in-treatment data have been previously described in more detail elsewhere.13 Of relevance to the present study, men and women overall did not differ in their age, proportion of days of cocaine and alcohol use in treatment, and treatment attrition rates.
Women did significantly report nausea more frequently (t=2.17, df=152, p=0.02) and higher psychiatric severity (t=2.13, df=154, p=0.04) than men (Table 1). However, within the medication groups, different patterns emerged between men and women on outcome-related variables, in particular, treatment attrition.
Table 1
Table 1
Gender Differences in Baseline, Predictor and Dependent Variables.
Predictors of Treatment Attrition
Results of logistic regression of treatment attrition for men and women with the six main predictors (i.e., medication treatment, psychosocial therapies, psychiatric severity, nausea reporting, cocaine use and alcohol use) are presented in Table 2. The final models for men and women from the backward stepwise elimination analyses are presented in Table 3.
Table 2
Table 2
Logistic Regression Odds Ratio (OR) and 95% Confidence Intervals for Predicting Treatment Attrition.
Table 3
Table 3
Logistic Regression Odds Ratio (OR) and 95% CI for Remaining Variables in the Final Model for Men and Women.
In a model containing all six predictors for women, the overall likelihood ratio (G statistic) was 46.41 (d.f.=6) and X2 (6) = 11.30 (p=0.08) (Table 3). Backward elimination began with a full model containing all variables, and the final model for women included psychiatric severity and frequency of nausea (X2 = 8.18, p=0.02) (Table 4). The estimated odd ratios (OR) and 95% CI were calculated for both variables. Women with higher psychiatric severity (OR = 23.89, 95% CI=1.04 to 547.27, p= 0.05) and higher frequency of nausea (OR = 43.45, 95% CI = 1.01 to 1864.43, p= 0.05) were more likely to dropout from the treatment.
For men, the overall likelihood ratio (G statistic) for a model containing the six variables was 123.36 (d.f.=6) and X2 (6) = 13.18 (p=0.04) (Table 3). In a backward stepwise elimination analysis, the final model contained both medication group and psychosocial therapy group as the significant factors predicting the treatment attrition (130.16, d.f. = 6; X2 (6) = 6.38, p=0.04). The results suggest that the men who were assigned to placebo condition (OR = 0.47, 95% CI=0.21 to 1.08, p= 0.08) and the men who were assigned to BRENDA condition (OR = .50, 95% CI=0.22 to 1.14, p= 0.10) were more likely to dropout from the treatment than those who were assigned to either naltrexone or CBT, respectively (Table 4).
Previously, Pettinati et al.13 found that CAD women and men had different treatment outcomes with high-dose naltrexone treatment, in which CAD men reduced their cocaine and alcohol use whereas women did not. In the present exploratory study, we attempted to investigate potential explanations for the gender differences in outcome, focusing on treatment attrition.
Our findings indicate that women generally reported nausea more frequently than men. While the overall attrition differences between men and women were not statistically significant, the differential rates of attrition between the subgroup of naltrexone-treated men and women approached significance. In attempting to predict treatment attrition, we found that men receiving placebo treatment and BRENDA were more likely to discontinue treatment. However, women reporting higher psychiatric problem severity and more frequent bouts with nausea in treatment were more likely to dropout from treatment.
In our study, high psychiatric severity was a predictor for CAD women discontinuing the treatment. Women obtained significantly higher psychiatric severity scores than men at baseline. Sixty-three percent of women and 46% of men reported high psychiatric symptoms prior to entering the treatment. If psychiatric severity, as demonstrated in our analysis, is making a significant impact on treatment attrition (and, subsequently, on their substance use), female patients with pre-treatment psychiatric symptoms may require symptom management (e.g., pharmacotherapy or psychotherapy) at the onset of substance use treatment. This would be an important clinical issue, given the high prevalence co-occurring substance use and mental disorders.34, 35
In general, the research findings on attrition rates between male and female substance abusers in various treatment settings are mixed.18, 19, 36, 37 In a recent injectable naltrexone trial using various doses, nausea was the only adverse event (AE) that occurred differentially for women and men in 10% or more patients, and the rate of nausea was significantly higher for women at a higher dosage (vs. placebo).11 Additionally, higher doses of naltrexone (vs. lower doses and placebo) resulted in higher rate of treatment discontinuation, secondary to adverse events (e.g., nausea), although the difference in attrition was not examined between men and women.11 Our findings are in line with those found in naltrexone-treated, alcohol dependent patients from O’Malley et al.,8 who previously reported that female alcohol dependent patients receiving naltrexone (50mg) were 7.2 times more likely to experience nausea than male patients, and that experiences of nausea was significantly associated with poor medication adherence and treatment discontinuation. These findings suggest that high-dose naltrexone treatment affects women differently.8, 38, 39 Due to sample size limitations, potential interaction effects of nausea and gender with treatment condition (naltrexone vs. placebo) on attrition were not examined. However, our data suggest there exist differential, though non-significant rates of both nausea and psychiatric severity for men and women in the two different treatment conditions. Future trials using naltrexone in female alcohol disordered patients, with or without cocaine dependence should focus on the impact of nausea and psychiatric problems on treatment attrition and treatment response.
Although our results have a number of potential implications for treating female CAD patients with high-dose naltrexone, due to the exploratory nature of the study, we cannot come to a definite conclusion. Clinically, our findings indicate that female CAD patients may require closer supervision during high-dose naltrexone treatment, especially given the possibility of gender effect in one naltrexone trial with large enough female alcoholic sample.11 In one recent preclinical study with rhesus macaques,40 a variant of the μ-opioid receptor gene (OPRM1C77G) was linked to increased alcohol consumption and preference, as well as alcohol intoxication, in male macaques only; this gender effect suggests μ-opioid receptor blockade may impact alcohol consumption and treatment response dissimilarly for men and women. Preliminary genetic research investigations indicate that alcohol dependent patients with certain genotypes respond better to naltrexone than those without comparable genetic profiles.4143 Identifying specific genotypes of CAD women, who do not experience naltrexone-associated side effects and who responds positively to naltrexone treatment, would enhance the effectiveness of high-dose naltrexone treatment (on genomic approach, see O’Brien (2008)).44
The interpretation of our findings needs to be examined in light of the following methodological limitations. First, our findings are specific to outpatient treatment-seeking CAD patients, and may not be representative of the general CAD population. Second, the ratio between male and female subjects in our sample was unbalanced. The number of female subjects was small, although this male-female distribution is within the expected range in the treatment sample.8, 36 Due to these sample-related limitations, we were only able to conduct two separate logistic regression analyses, each for men and women, rather than directly examining the interaction effects between gender and the predictors in our regression model. Similarly, potentially relevant interactional term, such as the interactional effect between cocaine or alcohol use and gender, was not included in the model due to sample size limitations. Given that this is an exploratory study, further research is needed to examine any gender differences in naltrexone treatment using an ample and a comparable number of female subjects per group to investigate the gender interaction. Third, although the use of logistic regression is the most appropriate statistical test in our investigation, the backward stepwise elimination procedures require a number of statistical tests. Thus, additional predictors increase the likelihood of Type I error occurring in analyses. It is recommended that cross-validation samples be conducted in future investigations, in order to reduce the risk of Type I error.
In conclusion, our findings showed a significant relationship between treatment discontinuation, and psychiatric problem severity and frequency of nausea in CAD women in high-dose naltrexone treatment. For men, those in placebo and BRENDA treatments were more likely to discontinue treatment. Further research is needed on how outcomes may be affected by gender differences in pre-treatment characteristics as well as potential pharmacokinetic-differential effects of high-dose naltrexone.
Acknowledgments
This investigation was supported, in part, by grants from the National Institute of Drug Abuse (P60-DA-05186-17; P50-DA-012756-04; T32-DA-07241-13), the National Institute of Alcohol Abuse and Alcoholism (R01-AA09544-07; R01-AA-014657-01), and the Veterans Affairs Medical Center-Philadelphia.
A preliminary analysis of the data was presented at the 67th Annual Scientific Meeting of the College on Problems of Drug Dependence in Orlando, FL, June 2005.
The authors thank Thomas Whittingham for his statistical assistance and Dr. Kevin Lynch (University of Pennsylvania) for comments.
1. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881–887. [PubMed]
2. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876–880. [PubMed]
3. Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004 Jul;99(7):811–828. [PubMed]
4. Modesto-Lowe V, Van Kirk J. Clinical uses of naltrexone: a review of the evidence. Exp Clin Psychopharmacol. 2002 Aug;10(3):213–227. [PubMed]
5. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. Jama. 1999 Apr 14;281(14):1318–1325. [PubMed]
6. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000 Nov–Dec;35(6):587–593. [PubMed]
7. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. 1997 Aug;54(8):737–742. [PubMed]
8. O'Malley SS, Krishnan-Sarin S, Farren C, O'Connor PG. Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol. 2000 Feb;20(1):69–76. [PubMed]
9. Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res. 2000 Oct;24(10):1542–1549. [PubMed]
10. Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology (Berl) 2001 Apr;154(4):397–402. [PubMed]
11. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. Jama. 2005 Apr 6;293(13):1617–1625. [PubMed]
12. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 3;295(17):2003–2017. [PubMed]
13. Pettinati HM, Kampman KM, Lynch KG, et al. Gender differences with high-dose naltrexone in the patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat. 2008 Jun;34(4):378–390. [PMC free article] [PubMed]
14. Johnson BA, O'Malley SS, Ciraulo DA, et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol. 2003 Jun;23(3):281–293. [PubMed]
15. Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR. Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res. 2006 May;30(5):860–865. [PubMed]
16. Denier CA, Thevos AK, Latham PK, Randall CL. Psychosocial and psychopathology differences in hospitalized male and female cocaine abusers: a retrospective chart review. Addictive Behaviors. 1991;16(6):489–496. [PubMed]
17. McKay JR, Rutherford MJ, Cacciola JS, Kabasakalian-McKay R, Alterman AI. Gender differences in the relapse experiences of cocaine patients. J Nerv Ment Dis. 1996 Oct;184(10):616–622. [PubMed]
18. Arfken CL, Klein C, di Menza S, Schuster CR. Gender differences in problem severity at assessment and treatment retention. J Subst Abuse Treat. 2001 Jan;20(1):53–57. [PubMed]
19. McKay JR, Lynch KG, Pettinati HM, Shepard DS. An examination of potential sex and race effects in a study of continuing care for alcohol- and cocaine-dependent patients. Alcohol Clin Exp Res. 2003 Aug;27(8):1321–1323. [PubMed]
20. Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004 Jun 11;74(3):265–272. [PubMed]
21. Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl. 2005 Jul;(15):170–178. discussion 168–179. [PubMed]
22. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders - Subject Edition (SCID-I/P, Version 2.0) New York, New York: Biometrics Research Department New York State Psychiatric Institute; 1996.
23. Sobell LC, Maisto SA, Sobell MB, Cooper AM. Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther. 1979;17(2):157–160. [PubMed]
24. Maisto SA, Sobell LC, Sobell MB. Comparison of alcoholics' self-reports of drinking behavior with reports of collateral informants. J Consult Clin Psychol. 1979;47(1):106–112. [PubMed]
25. Ehrman RN, Robbins SJ. Reliability and validity of 6-month timeline reports of cocaine and heroin use in a methadone population. J Consult Clin Psychol. 1994;62(4):843–850. [PubMed]
26. Fals-Stewart W, O'Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol. 2000 Feb;68(1):134–144. [PubMed]
27. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199–213. [PubMed]
28. Alterman AI, Brown LS, Zaballero A, McKay JR. Interviewer severity ratings and composite scores of the ASI: a further look. Drug Alcohol Depend. 1994 Feb;34(3):201–209. [PubMed]
29. McLellan AT, Luborsky L, Cacciola J, et al. New data from the Addiction Severity Index. Reliability and validity in three centers. J Nerv Ment Dis. 1985 Jul;173(7):412–423. [PubMed]
30. Marlatt GA, Gordon JR. Relapse prevention. New York, New York: Guilford Press; 1985.
31. Carroll KM. A Cognitive-Behavioral Approach: Treating Cocaine Addiction. Rockville, MD: National Institute on Drug Abuse; 1998.
32. Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP. Combining medication and psychosocial treatments for addictions: The BRENDA approach. New York, NY: Guilford Press; 2001.
33. Shoptaw S, Kintaudi PC, Charuvastra C, Ling W. A screening trial of amantadine as a medication for cocaine dependence. Drug Alcohol Depend. 2002;66:217–224. [PubMed]
34. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004 Aug;61(8):807–816. [PubMed]
35. O'Brien CP, Charney DS, Lewis L, et al. Priority actions to improve the care of persons with co-occuring substance abuse and other mental disorders: a call to action. Biological Psychiatry. 2004 November 15;56(10):703–713. 2004. [PubMed]
36. Wong CJ, Badger GJ, Sigmon SC, Higgins ST. Examining possible gender differences among cocaine-dependent outpatients. Exp Clin Psychopharmacol. 2002 Aug;10(3):316–323. [PubMed]
37. Hser YI, Huang D, Teruya C, Douglas Anglin M. Gender comparisons of drug abuse treatment outcomes and predictors. Drug Alcohol Depend. 2003 Dec 11;72(3):255–264. [PubMed]
38. Froehlich J, O'Malley S, Hyytia P, Davidson D, Farren C. Preclinical and clinical studies on naltrexone: what have they taught each other? Alcohol Clin Exp Res. 2003 Mar;27(3):533–539. [PubMed]
39. Klein LC, Jamner LD, Alberts J, Orenstein MD, Levine L, Leigh H. Sex differences in salivary cortisol levels following naltrexone administration. Journal of Applied Biobehavioral Research. 2000;5:144–153.
40. Barr CS, Schwandt M, Lindell SG, et al. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry. 2007 Mar;64(3):369–376. [PubMed]
41. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003 Aug;28(8):1546–1552. [PubMed]
42. Oslin DW, Berrettini WH, O'Brien CP. Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict Biol. 2006 Sep–Dec;11(3–4):397–403. [PubMed]
43. Anton RF, Oroszi G, O'Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135–144. [PMC free article] [PubMed]
44. O'Brien CP. Prospects for a genomic approach to the treatment of alcoholism. Arch Gen Psychiatry. 2008 Feb;65(2):132–133. [PubMed]